3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
CNS
1
Conditions
Carcinoma, Non-Small-Cell Lung
7
Lung Neoplasms
3
Respiratory Tract Diseases
1
Osteosarcoma
1
Neoplasms
1
Neoplasm Metastasis
1
Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer
1
EGFR-mutant Non-small Cell Lung Cancer
1
Brain Neoplasms
1
Adenocarcinoma of Lung
1
Interventions
Radiosurgery
50
Magnetic Resonance Spectroscopy
34
Temozolomide
28
Bevacizumab
24
pembrolizumab
23
Radiotherapy
20
Nivolumab
20
Specimen Handling
14
Ipilimumab
13
Cyclophosphamide
13
Mental Status and Dementia Tests
12
Carboplatin
12
abemaciclib
10
Radiation
10
trastuzumab deruxtecan
8
Proton Therapy
7
Pemetrexed
7
Memantine
7
Blood Specimen Collection
7
fluciclovine F-18
6
binimetinib
6
Paclitaxel
6
Lomustine
6
Etoposide
6
Cisplatin
6
Capecitabine
6
encorafenib
5
Trastuzumab
5
Surveys and Questionnaires
5
Surgical Procedures, Operative
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Brain Neoplasms
×
Gefitinib
×
1 year
×
Clear all
NCT03653546
2025-09-10
BM
Alpha Biopharma (Jiangsu) Co., Ltd.
Phase 2/3
Completed
492 enrolled